Skip to main content

Table 2 Furosemide trials

From: Evaluation of furosemide regimens in neonates treated with extracorporeal membrane oxygenation

Furosemide Singh [5] prospective RCT 24 hours (1992) Luciano [6] prospective RCT 24 hours (1997) Klinge [7] prospective RCT 72 hours (1997)    van der Vorst [8] prospective observational 72 hours (2001)   
Intermittent         
Patients (n) 12 15 23      
Continuous         
Patients (n) 8 11 23    12   
Intermittent         
Age 1.44 (± 1.4) years 3.7 (± 3.4) months 2.4 (± 2.1) years    13 (0–33) weeksa   
Continuous         
Age 2.3 (± 2.2) years 1.8 (± 2.5) months 3.4 (± 3.1) years      
P value NS 0.1 NS      
Study day    1 2 3 1 2 3
Intermittent dose mg/kg per 24 hours 6.23 (± 0.62) 6.8 (± 1.2) 1.6 (± 0.6) 0.9 (± 0.5) 1.0 (± 0.5)    
Continuous dose mg/kg per 24 hours       2.2 (± 0.4) 4.2 (± 1.1) 3.6 (± 1.3)
P value 0.045 0.001 0.014 0.0003 0.014    
Intermittent UO (ml/kg per hour) 3.53 (± 4.1) 3.3 (± 1.1) 3.1 (± 0.8) 2.9 (± 1.1) 2.9 (± 1.0)    
Continuous UO (ml/kg per hour) 3.36 (± 1.79) 2.5 (± 1.1) 2.7 (± 0.8) 2.9 (± 0.9) 3.6 (± 1.1) 2.4 (0.6–5.2)a 5.8 (3.5–9.1)a 5.4 (3.6–7.4)a
P value NS 0.05 NS NS NS    
Intermittent UO/variance 13.07 (± 14.56) ml/kg per hour 3.8 (± 2.1)       
Intermittent UO/variance maximal    15.8 (± 3.7) ml/kg per hour      
Intermittent UO/variance minimal    0.3 (± 0.2) ml/kg per hour      
Continuous UO/variance 2.19 (± 1.92) ml/kg per hour 1.9 (± 1.6)       
Continuous UO/variance maximal    9.4 (± 4.1) ml/kg per hour      
Continuous UO/variance minimal    0.5 (± 0.3) ml/kg per hour      
P value 0.045 0.02 < 0.0001      
  1. aMedian (range). Data given as mean (standard deviation) unless indicated otherwise. NS, not significant; RCT, randomised controlled trial; UO, urine output.